These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35100237)

  • 1. In brief: Abemaciclib (Verzenio) for early breast cancer.
    Med Lett Drugs Ther; 2021 Dec; 63(1639):199-200. PubMed ID: 35100237
    [No Abstract]   [Full Text] [Related]  

  • 2. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):185-186. PubMed ID: 29125595
    [No Abstract]   [Full Text] [Related]  

  • 3. In brief: A new indication for abemaciclib (Verzenio).
    Med Lett Drugs Ther; 2023 Apr; 65(1673):e62-e63. PubMed ID: 37020345
    [No Abstract]   [Full Text] [Related]  

  • 4. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
    Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2- Early Breast Cancer.
    Oncologist; 2021 Feb; 26 Suppl 2(Suppl 2):S5-S6. PubMed ID: 33399254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
    Palumbo A; Lau G; Saraceni M
    Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
    Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
    Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
    Petrelli F; Ghidini A; Pedersini R; Cabiddu M; Borgonovo K; Parati MC; Ghilardi M; Amoroso V; Berruti A; Barni S
    Breast Cancer Res Treat; 2019 Apr; 174(3):597-604. PubMed ID: 30659432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
    Hamilton E; Cortes J; Ozyilkan O; Chen SC; Petrakova K; Manikhas A; Jerusalem G; Hegg R; Huober J; Chapman SC; Lu Y; Hardebeck MC; Bear MM; Johnston EL; Martin M
    Clin Breast Cancer; 2021 Jun; 21(3):181-190.e2. PubMed ID: 33148479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Agent Abemaciclib Active in Breast Cancer.
    Cancer Discov; 2016 Aug; 6(8):809-10. PubMed ID: 27354271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
    Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abemaciclib for the treatment of breast cancer.
    Kotake T; Toi M
    Expert Opin Pharmacother; 2018 Apr; 19(5):517-524. PubMed ID: 29522364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abemaciclib Shows Promise for Early Breast Cancer.
    Cancer Discov; 2017 Feb; 7(2):119-120. PubMed ID: 27986713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abemaciclib: First Global Approval.
    Kim ES
    Drugs; 2017 Dec; 77(18):2063-2070. PubMed ID: 29128965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
    El Rassy E; Bakouny Z; Assi T; Kattan J
    Future Oncol; 2018 Apr; 14(9):891-895. PubMed ID: 29527939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
    Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S
    Gan To Kagaku Ryoho; 2021 Dec; 48(12):1475-1483. PubMed ID: 34911915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.